ORIC Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Rinzimetostat at 400 mg daily with darolutamide showed strong efficacy and a highly differentiated safety profile in mCRPC, supporting its selection as the phase III dose. Landmark RPFS and ctDNA responses were robust, and safety was superior to competitor regimens, positioning it for significant commercial potential.
-
Two clinical-stage oncology programs are advancing, with rinzimetostat set for a phase III prostate cancer trial and enosertinib showing strong CNS activity in lung cancer. Key data updates and competitor readouts this year will shape future strategies and potential market expansion.
-
Development is advancing for two lead oncology programs, with phase III trials and key data updates planned for 2024. Early clinical results show promising efficacy and safety, and the company is well-funded through 2028 to support these milestones.
-
Two late-stage oncology assets are advancing to phase III, with rinzimetostat showing strong efficacy and safety in prostate cancer and enozertinib demonstrating 100% intracranial response in lung cancer. Key data readouts and trial initiations are expected in 2025-2027.
Fiscal Year 2025
-
ORIC-114 shows strong systemic and CNS efficacy in EGFR-mutated NSCLC, with high response rates and a favorable safety profile at 80 mg. The drug’s robust brain penetrance and lack of significant off-target toxicities position it as a potential best-in-class therapy, with Phase 3 trials planned and a significant commercial opportunity projected.
-
Significant clinical progress was made in 2025, with ORIC-944 showing promising efficacy and safety in prostate cancer and ORIC-114 poised for key data at ESMO Asia. The company is well-funded, planning a phase III start for ORIC-944 in early 2026, and sees substantial market opportunities in both programs.
-
Lead oncology programs are advancing toward phase III, with ORIC-944 showing strong efficacy, safety, and ctDNA clearance in prostate cancer. ORIC-114 is progressing in lung cancer, with pivotal studies planned for both assets and a cash runway into 2028.
-
Development priorities center on prostate and lung cancer, with two main clinical programs advancing toward phase III. ORIC-944 shows promising efficacy and safety in prostate cancer, while ORIC-114 targets multiple lung cancer populations with key data updates ahead. Financing is secured, and strategic partnerships may support further expansion.
-
Lead oncology programs are advancing toward phase 3, with ORIC-944 showing promising efficacy and safety in prostate cancer and ORIC-114 differentiated by CNS activity in lung cancer. Both programs are well-funded, with major data readouts and pivotal trial starts expected in the next year.
-
ORIC’s two lead oncology programs are advancing toward Phase 3, with ORIC-944 showing promising efficacy and safety in prostate cancer and ORIC-114 demonstrating CNS activity in NSCLC. The company is well-funded through 2028 and is pursuing flexible partnership strategies.
-
The company is advancing two lead oncology programs: ORIC-944 for prostate cancer, showing promising early efficacy and safety versus competitors, and ORIC-114 for lung cancer, with upcoming data focused on CNS activity and response rates. Strong financials support development through key phase III milestones.
-
Two clinical-stage programs are advancing toward phase 3, with ORIC-944 showing promising efficacy and tolerability in prostate cancer and ORIC-114 targeting brain-penetrant lung cancer populations. Key data updates and dose selections are expected soon, with a strong financial runway supporting development.
-
Two lead programs are advancing in prostate and lung cancer, with multiple clinical readouts and phase three trial initiations planned for 2026. ORIC-944 shows promising efficacy and safety, while ORIC-114 demonstrates strong brain penetrance and activity in difficult mutations. Financial runway extends into 2027.
-
Key programs in prostate and lung cancer are advancing, with ORIC-944 showing strong early efficacy and safety compared to benchmarks. Dose optimization and pivotal study planning are underway, with major data updates expected in late 2024. Cash runway extends into 2027.
-
Revised summary: ORIC-944, a next-generation PRC2 inhibitor, showed promising safety and efficacy with apalutamide or darolutamide in heavily pretreated mCRPC patients, with PSA50 and PSA90 response rates of 47% and 24%. Dose optimization and phase III are planned, with expansion into other cancers supported by strong preclinical data.
-
The event detailed progress on PRC2 inhibitor development for prostate cancer, highlighting ORIC-944's competitive profile and plans for pivotal studies in 2026. Upcoming data will benchmark PSA responses against Pfizer's results, with a focus on expanding market opportunities and regulatory pathways.
-
The session highlighted a robust oncology pipeline with two lead programs: ORIC-944, a PRC2 inhibitor in prostate cancer showing promising early efficacy and safety, and ORIC-114, a CNS-penetrant TKI for lung cancer mutations with early clinical activity. Key data readouts and pivotal trial decisions are expected in 2025 and 2026.
-
Pfizer's MEVPRO data validate PRC2 inhibition in prostate cancer, with ORIC-944 positioned to address PK and safety gaps. ORIC plans to initiate phase 3 trials next year, supported by strong cash reserves and multiple upcoming data readouts for both ORIC-944 and ORIC-114.
-
Key programs target resistance in prostate and lung cancer, with promising early efficacy and safety data for ORIC-944 in prostate cancer and ongoing dose expansion for ORIC-114 in lung cancer. Strategic collaborations and multiple data readouts are expected in 2024–2025.
-
Two lead oncology programs are advancing toward pivotal studies: ORIC-114, a brain-penetrant lung cancer therapy, and ORIC-944, a PRC2 inhibitor for prostate cancer, both showing promising early efficacy and safety. Multiple data readouts and a strong cash position support accelerated development.
Fiscal Year 2024
-
Panelists highlighted recent approvals of novel oncology agents, robust pipelines, and the importance of biomarker-driven strategies and rational combinations. AI is increasingly used for patient identification and data analysis, while business development remains a key growth driver.
-
ORIC-114 aims to address key safety and CNS challenges in NSCLC, with pivotal trial decisions expected in 2025 and regulatory submission targeted for 2027. ORIC-944, a PRC2 inhibitor, is positioned to compete with Pfizer's EZH2 program, with phase 3 studies planned by late 2025 or early 2026.
-
Two lead programs are advancing toward pivotal studies, with ORIC-944 showing favorable pharmacokinetics and broad AR inhibitor compatibility, and ORIC-114 targeting key lung cancer mutations with a focus on CNS activity. Both programs expect critical data updates and potential registration study starts in the second half of next year.
-
The company is advancing two clinical programs: ORIC-114, a brain-penetrant EGFR/HER2 inhibitor for lung cancer, and ORIC-944, a PRC2 inhibitor for prostate cancer. Key differentiators include CNS activity and targeting underserved patient populations, with pivotal data and potential phase 3 starts expected in 2025.
-
Two lead programs are advancing: ORIC-944, a next-gen PRC2 inhibitor for prostate cancer, and ORIC-114, a brain-penetrant targeted therapy for EGFR/HER2 mutant cancers. Both are in dose optimization, with registrational studies planned for late 2025 and strong financial runway.
-
The company is advancing two lead oncology programs: ORIC-114, a brain-penetrant EGFR/HER2 exon 20 inhibitor with promising early data and a potential accelerated approval path, and ORIC-944, a PRC2 inhibitor for prostate cancer now moving into combination studies. Financial runway extends into late 2026, with registrational studies planned for both programs next year.
-
The company is advancing two lead programs: ORIC-114, a brain-penetrant TKI targeting EGFR/HER2 mutations in lung cancer, and ORIC-944, a PRC2 inhibitor for prostate cancer. ORIC-114 has shown promising CNS activity and safety, with registrational studies planned for 2025. Financially, the firm is well-capitalized to support these initiatives.
-
Two lead programs, ORIC-944 and ORIC-114, are advancing based on strong preclinical and clinical data, with ORIC-944 showing superior drug properties and ORIC-114 demonstrating CNS activity in hard-to-treat mutations. Key data updates are expected mid-2024 and 1H 2025.